International Clinical Trial: A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07465263) titled 'A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)' on March 6.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Condition: Heterozygous Familial Hypercholesterolemia (HeFH)

Intervention: Drug: SYH2053 Injection

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: March 31, 2026

Target Samp...